{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:49:06Z","timestamp":1770788946653,"version":"3.50.0"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","award":["IIS-PEARL 60"],"award-info":[{"award-number":["IIS-PEARL 60"]}],"id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024493","name":"Department of Medicine, University of Malaya","doi-asserted-by":"publisher","award":["DOMRSF-2022-02"],"award-info":[{"award-number":["DOMRSF-2022-02"]}],"id":[{"id":"10.13039\/501100024493","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Older adults exhibit heterogeneous immune responses to COVID-19 vaccination, yet the relative contributions of age, comorbidity, vaccine platform, and infection history to antibody durability remain incompletely defined. Understanding these determinants is essential to inform booster strategies in ageing populations. We conducted a longitudinal observational study of 300 participants (250 aged \u226560 years and 50 younger controls) followed for up to 15 months. Anti-spike (anti-S) antibody responses were assessed at four event-anchored timepoints:\u2009\u2264\u20093 months post-primary vaccination (TP1),\u2009~\u20093 months post-first booster (TP2), 6\u20139 months post-first booster capturing waning immunity (TP3), and \u22643 months post-second booster where available (TP4). Multivariable log-linear regression models were used to identify independent determinants of antibody levels, with additional analyses stratified by infection status and vaccine platform. Among older adults, 78.8% had moderate-to-severe comorbidity burden, 40.0% were pre-frail, and only 16.8% received a second booster. At TP3, older age was associated with lower antibody levels in univariable analysis (GMR 0.81, 95% CI 0.68\u20130.97) but not after adjustment (aGMR 0.78, 95% CI 0.51\u20131.22, p\u2009=\u20090.279). Independent predictors of higher TP3 antibody levels included female sex (aGMR 1.24, 95% CI 1.02\u20131.51, p\u2009=\u20090.028), prior SARS-CoV-2 infection (aGMR 1.39, 95% CI 1.14\u20131.71, p\u2009=\u20090.001), and mRNA (aGMR 5.16, 95% CI 3.57\u20137.47, p=&lt;0.001) or viral vector boosters (aGMR 6.05, 95% CI 4.03\u20139.08, p=&lt;0.001), while renal disease was associated with lower responses (aGMR 0.71, 95% CI 0.54\u20130.94, p\u2009=\u20090.017). Similar associations were observed at TP4. Frailty and sarcopenia were not independently associated with antibody levels. Neutralising antibodies against Omicron were absent after primary vaccination and detected in only 25.9% of infection-na\u00efve older adults after the first booster. Sustained humoral immunity following COVID-19 vaccination is driven primarily by vaccine platform and immune history rather than chronological age or geriatric syndromes alone. Waning immunity unmasks vulnerability in older adults, while low uptake of second boosters highlights a critical gap between immunological risk and vaccine utilisation. These findings support targeted, equity-focused booster strategies prioritising highly immunogenic platforms and high-risk older adults.<\/jats:p>","DOI":"10.1371\/journal.pone.0340891","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:29:21Z","timestamp":1770748161000},"page":"e0340891","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective Evaluation of Antibody Response post COVID-19 vaccination in older persons \u2267 60 years old (PEARL 60): A longitudinal 15-months study in a tertiary centre in Malaysia"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6279-3999","authenticated-orcid":true,"given":"Kejal","family":"Hasmukharay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh Kumar","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiirtaara","family":"Aravindhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakhaash Raaj S.","family":"Alagappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisya Karynna Md","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurul Syuhada","family":"Zulhaimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-7934","authenticated-orcid":true,"given":"Nor Izzati","family":"Saedon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamal","family":"I-Ching-Sam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tan Maw","family":"Pin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena","family":"Rajasuriar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"pone.0340891.ref001","unstructured":"WHO. COVID 19 Dashboard Geneva: World Health Organisation(WHO). 2025 [updated 4th May 2025. Available from: https:\/\/covid19.who.int\/"},{"key":"pone.0340891.ref002","unstructured":"MOH. COVID 19 2025 [updated 4th May 2025. Available from: https:\/\/data.moh.gov.my\/dashboard\/covid-19"},{"issue":"2","key":"pone.0340891.ref003","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3947\/ic.2020.52.2.154","article-title":"Age-Related Morbidity and Mortality among Patients with COVID-19","volume":"52","author":"SJ Kang","year":"2020","journal-title":"Infect Chemother"},{"issue":"7","key":"pone.0340891.ref004","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jamda.2020.05.045","article-title":"The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects","volume":"21","author":"C Bonanad","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"pone.0340891.ref005","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/CIA.S295522","article-title":"Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist","volume":"16","author":"MK Andrew","year":"2021","journal-title":"Clin Interv Aging"},{"issue":"7","key":"pone.0340891.ref006","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"DS Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"pone.0340891.ref007","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","article-title":"Looking beyond COVID-19 vaccine phase 3 trials","volume":"27","author":"JH Kim","year":"2021","journal-title":"Nat Med"},{"key":"pone.0340891.ref008","first-page":"26","volume-title":"Interdisciplinary topics in gerontology and geriatrics","author":"T Fulop","year":"2015"},{"issue":"3","key":"pone.0340891.ref009","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jgs.16917","article-title":"Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals","volume":"69","author":"D Curran","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"pone.0340891.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094578","article-title":"A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly","volume":"9","author":"CR Macintyre","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"pone.0340891.ref011","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/infdis\/jix282","article-title":"The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People","volume":"216","author":"MK Andrew","year":"2017","journal-title":"J Infect Dis"},{"key":"pone.0340891.ref012","article-title":"Frailty and Age Impact Immune Responses to Moderna COVID-19 mRNA Vaccine","author":"CT Semelka","year":"2022","journal-title":"Research Square"},{"issue":"9","key":"pone.0340891.ref013","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s43587-021-00114-7","article-title":"SARS-CoV-2, COVID-19 and the Ageing Immune System","volume":"1","author":"JM Bartleson","year":"2021","journal-title":"Nat Aging"},{"issue":"7872","key":"pone.0340891.ref014","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","volume":"596","author":"DA Collier","year":"2021","journal-title":"Nature"},{"issue":"9","key":"pone.0340891.ref015","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/jama.2021.11656","volume":"326","author":"TA Bates","year":"2021","journal-title":"Jama"},{"issue":"4","key":"pone.0340891.ref016","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-7568(22)00035-6","article-title":"Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort","volume":"3","author":"L Arregoc\u00e9s-Castillo","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"pone.0340891.ref017","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"D Cromer","year":"2022","journal-title":"Lancet Microbe"},{"issue":"1","key":"pone.0340891.ref018","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1038\/s41598-022-07849-2","article-title":"Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents","volume":"12","author":"B S\u00e1nchez-Sendra","year":"2022","journal-title":"Sci Rep"},{"key":"pone.0340891.ref019","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.03.010","article-title":"Sample Size Estimation in Clinical Research: From Randomized Controlled Trials to Observational Studies","volume":"158","author":"X Wang","year":"2020","journal-title":"Chest"},{"issue":"7","key":"pone.0340891.ref020","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s12603-012-0084-2","article-title":"A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans","volume":"16","author":"JE Morley","year":"2012","journal-title":"J Nutr Health Aging"},{"issue":"1","key":"pone.0340891.ref021","first-page":"55","article-title":"Sarcopenia: The Target Population","volume":"2","author":"TK Malmstrom","year":"2013","journal-title":"J Frailty Aging"},{"issue":"6","key":"pone.0340891.ref022","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Z Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pone.0340891.ref023","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jama.2022.11844","article-title":"Mix-and-match COVID-19 boosters after inactivated virus vaccine","volume":"328","author":"HD Larkin","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"pone.0340891.ref024","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-022-30340-5","article-title":"Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant","volume":"13","author":"F Zuo","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"pone.0340891.ref025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/resp.14191","article-title":"Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong","volume":"27","author":"CKP Mok","year":"2022","journal-title":"Respirology"},{"issue":"4","key":"pone.0340891.ref026","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/resp.14236","article-title":"COVID-19 vaccine-induced immunity: Head-to-head comparison of mRNA (BNT162b2) versus inactivated (CoronaVac) vaccines","volume":"27","author":"B M Kagina","year":"2022","journal-title":"Respirology"},{"issue":"49","key":"pone.0340891.ref027","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.1073\/pnas.1805268115","article-title":"Biological sex affects vaccine efficacy and protection against influenza in mice","volume":"115","author":"AL Fink","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"pone.0340891.ref028","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and Gender Differences in the Outcomes of Vaccination over the Life Course","volume":"33","author":"KL Flanagan","year":"2017","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"13","key":"pone.0340891.ref029","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.vaccine.2011.01.071","article-title":"Sex differences in the vaccine-specific and non-targeted effects of vaccines","volume":"29","author":"KL Flanagan","year":"2011","journal-title":"Vaccine"},{"issue":"9","key":"pone.0340891.ref030","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jtct.2021.08.003","article-title":"Beginning to understand clinical events and immune responses of hematopoietic cell transplant recipients receiving SARS-CoV-2 vaccination","volume":"27","author":"J-AH Young","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"pone.0340891.ref031","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1128\/CVI.00123-08","article-title":"Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D","volume":"15","author":"X Zhang","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"pone.0340891.ref032","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"SL Klein","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pone.0340891.ref033","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12070439","article-title":"Immune dysfunction in uremia","volume":"12","author":"G Cohen","year":"2020","journal-title":"Toxins"},{"issue":"2","key":"pone.0340891.ref034","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1681\/ASN.2021091257","article-title":"Secondary Immunodeficiency Related to Kidney Disease (SIDKD)-Definition, Unmet Need, and Mechanisms","volume":"33","author":"S Steiger","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"pone.0340891.ref035","first-page":"1","article-title":"Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis","author":"M Biswas","year":"2020","journal-title":"Intervirology"},{"key":"pone.0340891.ref036","doi-asserted-by":"crossref","unstructured":"Huang CF, Jang TY, Wu PH, Kuo MC, Yeh ML, Wang CW. Impact of comorbidities on the serological response to COVID-19 vaccination in Taiwan. 2023.","DOI":"10.21203\/rs.3.rs-2411516\/v1"},{"issue":"6","key":"pone.0340891.ref037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0303303","article-title":"Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system","volume":"19","author":"TC Chervo","year":"2024","journal-title":"PLoS One"},{"issue":"7","key":"pone.0340891.ref038","doi-asserted-by":"crossref","first-page":"11180","DOI":"10.1021\/acsnano.1c03972","article-title":"Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses","volume":"15","author":"FJ Ibarrondo","year":"2021","journal-title":"ACS Nano"},{"key":"pone.0340891.ref039","doi-asserted-by":"crossref","unstructured":"Ebrahim F, Tabal S, Lamami Y, Alhudiri I, Meshri SEE, Dwigen SMA. Immunity post-Covid-19 recovery boosts the antibody immune response to SARS-CoV-2 vaccination. 2022.","DOI":"10.1101\/2022.02.18.22271130"},{"issue":"3","key":"pone.0340891.ref040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/v13030422","article-title":"Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection","volume":"13","author":"F Gobbi","year":"2021","journal-title":"Viruses"},{"issue":"19","key":"pone.0340891.ref041","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jama.2021.19623","article-title":"Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar","volume":"326","author":"LJ Abu-Raddad","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"pone.0340891.ref042","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.10780","article-title":"Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine","volume":"5","author":"K Furukawa","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"7898","key":"pone.0340891.ref043","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Y Cao","year":"2022","journal-title":"Nature"},{"issue":"6581","key":"pone.0340891.ref044","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera","volume":"375","author":"A Muik","year":"2022","journal-title":"Science"},{"issue":"1","key":"pone.0340891.ref045","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/22221751.2021.2022440","article-title":"Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost","volume":"11","author":"J Ai","year":"2022","journal-title":"Emerg Microbes Infect"},{"issue":"8","key":"pone.0340891.ref046","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway","volume":"7","author":"BJ Willett","year":"2022","journal-title":"Nat Microbiol"},{"key":"pone.0340891.ref047","doi-asserted-by":"crossref","first-page":"104158","DOI":"10.1016\/j.ebiom.2022.104158","article-title":"Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies","volume":"82","author":"A Wilhelm","year":"2022","journal-title":"EBioMedicine"},{"issue":"3","key":"pone.0340891.ref048","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/vaccines11030638","article-title":"COVID-19 Vaccine Booster Hesitancy in Malaysia: A Web-Based Cross-Sectional Study","volume":"11","author":"KW Lee","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"pone.0340891.ref049","doi-asserted-by":"crossref","unstructured":"Kakugawa T, Doi K, Ohteru Y, Kakugawa H, Oishi K, Kakugawa M. Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: A prospective longitudinal study. 2023.","DOI":"10.21203\/rs.3.rs-2962153\/v1"},{"key":"pone.0340891.ref050","first-page":"12","article-title":"Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People","author":"J Demaret","year":"2021","journal-title":"Frontiers in immunology"},{"issue":"1","key":"pone.0340891.ref051","doi-asserted-by":"crossref","DOI":"10.1186\/s12979-023-00327-x","article-title":"Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults","volume":"20","author":"C Semelka","year":"2023","journal-title":"Immunity & Ageing"},{"key":"pone.0340891.ref052","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac397","article-title":"Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine-Induced Immunity in Older Adults","volume":"75","author":"JR Shapiro","year":"2022","journal-title":"Clin Infect Dis"},{"key":"pone.0340891.ref053","doi-asserted-by":"crossref","first-page":"778679","DOI":"10.3389\/fimmu.2021.778679","article-title":"Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People","volume":"12","author":"J Demaret","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0340891.ref054","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10522-021-09944-9","article-title":"Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older residents of a long-term care facility: relation with age, frailty and prior infection status","volume":"23","author":"P Seiffert","year":"2022","journal-title":"Biogerontology"},{"issue":"3","key":"pone.0340891.ref055","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jamda.2021.12.001","article-title":"Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents","volume":"23","author":"AH Dyer","year":"2022","journal-title":"J Am Med Dir Assoc"},{"key":"pone.0340891.ref056","doi-asserted-by":"crossref","unstructured":"Knopp P, Miles A, Webb TE, McLoughlin BC, Mannan I, Raja N. Presenting features of COVID-19 in older people: relationships with frailty, inflammation and mortality. 2020.","DOI":"10.1101\/2020.06.07.20120527"},{"issue":"3","key":"pone.0340891.ref057","article-title":"Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study","volume":"3","author":"DC Vinh","year":"2022","journal-title":"Lancet Healthy Longev"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:29:30Z","timestamp":1770748170000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340891"}},"subtitle":[],"editor":[{"given":"Eleonora","family":"Nicolai","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340891","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}